Matches in Nanopublications for { ?s ?p "[Thus, the presence of ESO Ab identifies a tumor subtype of HR⁻ (HER2⁻ or HER2⁺) primary BC with frequent ESO expression and, together with the assessment of antigen expression in the tumor, may be instrumental for the selection of patients for whom ESO-based immunotherapy may complement standard therapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 2 of
2
with 100 items per page.
- NP935068.RAp3GFZ0obMV_kxM9km3RfkVAkRPJqGj9l-Q0XHg9V01k130_assertion description "[Thus, the presence of ESO Ab identifies a tumor subtype of HR⁻ (HER2⁻ or HER2⁺) primary BC with frequent ESO expression and, together with the assessment of antigen expression in the tumor, may be instrumental for the selection of patients for whom ESO-based immunotherapy may complement standard therapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP935068.RAp3GFZ0obMV_kxM9km3RfkVAkRPJqGj9l-Q0XHg9V01k130_provenance.
- NP387514.RALAHY0-Q4v8nV1aYKzHno0PocJbHXXadTuMNEF1Zrx9U130_assertion description "[Thus, the presence of ESO Ab identifies a tumor subtype of HR⁻ (HER2⁻ or HER2⁺) primary BC with frequent ESO expression and, together with the assessment of antigen expression in the tumor, may be instrumental for the selection of patients for whom ESO-based immunotherapy may complement standard therapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP387514.RALAHY0-Q4v8nV1aYKzHno0PocJbHXXadTuMNEF1Zrx9U130_provenance.